Performance of the self in the theatre of the elite - The King’s Theatre, 1760–1789:The opera house as a political and social nexus for women.

This research takes as its starting point the King’s Theatre in London, known as the Opera House, between 1760 and 1789. It examines the elite women subscribers who were on display and their approach to self-presentation in this social and political nexus. It makes a close examination of four women who sat in the audience at that time, as exemplars of the various experiences and approaches to attending the opera. Recent research has examined the performative offerings at the Opera House, the constitution of the audience and the troubled management of the theatre in that period. What is missing, is an examination of the power of the visual in confirming and maintaining status. As a group the women presented a united front as members of the ruling class, but as individuals they were under observation, as much from their peers as others in the audience and the visual dynamic of this display has not been analysed before. The research uses a combination of methodological approaches from a range of disciplines, including history, psychology and phenomenology, in order to extrapolate a sense of the experience for these women. It applies current understandings of the psychology of dress to writings of the women themselves and commentary from wider society, to build an understanding of the phenomenological experience of sitting at the opera under the gaze of the audience. The research brings to the field a greater understanding of the dynamic at play at the Opera House. It articulates in detail the importance of the visual to the women in that space and the pressures put on them by their class. It also adds to the understanding of the relationship between the performers, particularly dancers, and the subscribers in the audience. Each had an interest in maintaining the status of the Opera House as a theatre of the great

Evaluation of Households into Work Phase 2: final report

Households into Work (HiW) is an employment support programme led by Liverpool City Region Combined Authority (LCRCA). Clients are offered 1:1 bespoke support for up to 12 months, aimed at helping them identify and overcome the issues that are preventing them from seeking, considering or moving into employment, education or training. The issues faced by people on the programme are complex and varied including debt, finances, housing, mental health, domestic violence, addiction and isolation. HiW has been a key component of LCRCA’s employment and skills strategy since its inception. Phase 1 was a two-year pilot from 2018 to 2020, on the basis of which the programme was continued. This report is on the evaluation of HiW Phase 2, which ran from 1 October 2020 to 31 March 2023. The evaluation has been carried out by the University of Liverpool’s Heseltine Institute for Public Policy, Practice and Place, for the purposes of understanding the outcomes of Phase 2, tracking how the programme has evolved in response to various contextual changes, and informing current and potential future phases

Internet-Based Support for Cardiovascular Disease Management

With significant declines in cardiovascular disease (CVD) mortality, attention has shifted to patient management. Programs designed to manage CVD require the involvement of health professionals for comanagement and patients' self-management. However, these programs are commonly limited to large urban centers, resulting in limited access for rural patients. The use of telehealth potentially overcomes geographical barriers and can improve access to care for patients. The current research explores how an Internet-based platform might facilitate collaboration among healthcare providers comanaging patients and enhance behavioural change in patients. Forty-eight participants were interviewed including: (a) patients (n = 12), (b) physicians (n = 11), (c) nurses (n = 13), and (d) allied health professionals (n = 10). The results were organized and analyzed in three central themes: (1) role of technology for CVD management, (2) challenges to technology adoption, and (3) incentives for technology adoption. Health care providers and patients supported future implementation of Internet-based technology support for CVD management

Rare Genetic Variation in 135 Families With Family History Suggestive of X-Linked Intellectual Disability.

Families with multiple male children with intellectual disability (ID) are usually suspected of having disease due to a X-linked mode of inheritance and genetic studies focus on analysis of segregating variants in X-linked genes. However, the genetic cause of ID remains elusive in approximately 50% of affected individuals. Here, we report the analysis of next-generation sequencing data in 274 affected individuals from 135 families with a family history suggestive of X-linked ID. Genetic diagnoses were obtained for 19% (25/135) of the families, and 24% (33/135) had a variant of uncertain significance. In 12% of cases (16/135), the variants were not shared within the family, suggesting genetic heterogeneity and phenocopies are frequent. Of all the families with reportable variants (43%, 58/135), we observed that 55% (32/58) were in X-linked genes, but 38% (22/58) were in autosomal genes, while the remaining 7% (4/58) had multiple variants in genes with different modes on inheritance. This study highlights that in families with multiple affected males, X linkage should not be assumed, and both individuals should be considered, as different genetic etiologies are common in apparent familial cases

Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FcεRI-positive cells in the skin

Background. Treatment with omalizumab, a humanized recombinant monoclonal anti-IgE antibody, results in clinical efficacy in patients with Chronic Spontaneous Urticaria (CSU). The mechanism of action of omalizumab in CSU has not been elucidated in detail. Objectives. To determine the effects of omalizumab on levels of high affinity IgE receptor-positive (FcεRI+) and IgE- positive (IgE+) dermal cells and blood basophils. Treatment efficacy and safety were also assessed. Study design. In a double-blind study, CSU patients aged 18‑75 years were randomized to receive 300 mg omalizumab (n=20) or placebo (n=10) subcutaneously every 4 weeks for 12 weeks. Changes in disease activity were assessed by use of the weekly Urticaria Activity Score (UAS7). Circulating IgE levels, basophil numbers and levels of expression of FcεRI+ and IgE+ cells in the skin and in blood basophils were determined. Results. Patients receiving omalizumab showed a significantly greater decrease in UAS7 compared with patients receiving placebo. At Week 12 the mean difference in UAS7 between treatment groups was -14.82 (p=0.0027), consistent with previous studies. Total IgE levels in serum were increased after omalizumab treatment and remained elevated up to Week 12. Free IgE levels decreased after omalizumab treatment. Mean levels of FcεRI+ skin cells in patients treated with omalizumab 300 mg were decreased at Week 12 compared with baseline in the dermis of both non-lesional and lesional skin, reaching levels comparable with those seen in healthy volunteers (HVs). There were no statistically significant changes in mean FcɛRI+ cell levels in the placebo group. Similar results were seen for changes in IgE+ cells, although the changes were not statistically significant. The level of peripheral blood basophils increased immediately after treatment start and returned to Baseline values after the follow-up period. The levels of FcεRI and IgE expression on peripheral blood basophils were rapidly reduced by omalizumab treatment up to Week 12. Conclusions. Treatment with omalizumab resulted in rapid clinical benefits in patients with CSU. Treatment with omalizumab was associated with reduction in FcɛRI+ and IgE+ basophils and intradermal cells